KG006

KG006 is a next-generation FcRn inhibitor featuring a novel antibody structure designed for extended durability and potential best-in-class efficacy in the treatment of pathogenic antibody-mediated autoimmune diseases[1][4][5]. Unlike existing FcRn inhibitors, KG006 leverages Kaigene’s proprietary PDEG™ (Pathogenic Antibody Degrader) platform, which is optimized to selectively degrade pathogenic antibodies, a common driver of various autoimmune disorders[4]. As a nonclinical-stage asset, KG006 has not yet entered human trials, but it is positioned as a potential transformative therapy for autoimmune diseases where pathogenic antibodies play a key role[4].